questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de la phospholipase A2
Inhibiteurs de la phospholipase A2 : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la phospholipase A2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la phospholipase A2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-18",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "James A Shayman",
"url": "https://questionsmedicales.fr/author/James%20A%20Shayman",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu."
}
},
{
"@type": "Person",
"name": "Kathleen Fernandes Grego",
"url": "https://questionsmedicales.fr/author/Kathleen%20Fernandes%20Grego",
"affiliation": {
"@type": "Organization",
"name": "Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil."
}
},
{
"@type": "Person",
"name": "Akira Abe",
"url": "https://questionsmedicales.fr/author/Akira%20Abe",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu."
}
},
{
"@type": "Person",
"name": "Shulin Hou",
"url": "https://questionsmedicales.fr/author/Shulin%20Hou",
"affiliation": {
"@type": "Organization",
"name": "Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China."
}
},
{
"@type": "Person",
"name": "Junping Bai",
"url": "https://questionsmedicales.fr/author/Junping%20Bai",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis.",
"datePublished": "2022-06-10",
"url": "https://questionsmedicales.fr/article/35756924",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fneur.2022.858302"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety evaluation of the food enzyme phospholipase A2 from the genetically modified",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36743685",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2903/j.efsa.2023.7458"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36674864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24021353"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-phospholipase A2 Receptor Antibody-Negative Membranous Nephropathy in Pregnancy.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37664313",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.42827"
}
},
{
"@type": "ScholarlyArticle",
"name": "Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy.",
"datePublished": "2022-12-13",
"url": "https://questionsmedicales.fr/article/36938074",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ekir.2022.12.003"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de la phospholipase A2",
"item": "https://questionsmedicales.fr/mesh/D064801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la phospholipase A2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la phospholipase A2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la phospholipase A2",
"description": "Comment diagnostiquer une inhibition de la phospholipase A2 ?\nQuels tests sont utilisés pour évaluer l'inhibition ?\nY a-t-il des marqueurs spécifiques pour l'inhibition ?\nL'imagerie est-elle utile dans ce diagnostic ?\nQuels symptômes peuvent indiquer une inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?\nL'inhibition provoque-t-elle des douleurs articulaires ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la phospholipase A2",
"description": "Comment prévenir l'inhibition de la phospholipase A2 ?\nLes exercices physiques aident-ils à prévenir l'inhibition ?\nY a-t-il des habitudes à éviter ?\nLes compléments alimentaires sont-ils utiles ?\nLa gestion du stress peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la phospholipase A2",
"description": "Quels traitements existent pour inhiber la phospholipase A2 ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements naturels disponibles ?\nComment les inhibiteurs spécifiques sont-ils administrés ?\nLes traitements nécessitent-ils un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la phospholipase A2",
"description": "Quelles complications peuvent survenir avec l'inhibition ?\nL'inhibition peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques d'allergies ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à l'inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les facteurs de risque d'inhibition ?\nL'obésité est-elle un facteur de risque ?\nLe stress chronique influence-t-il l'inhibition ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064801?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition de la phospholipase A2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biochimiques mesurant l'activité de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inhibition ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages d'acides gras peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'inhibition ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs comme les cytokines peuvent indiquer une inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile dans ce diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est généralement pas utilisée pour diagnostiquer l'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une inhibition ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes inflammatoires comme la douleur ou le gonflement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, inflammation et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition provoque-t-elle des douleurs articulaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inhibition peut entraîner des douleurs articulaires dues à l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes digestifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles digestifs peuvent survenir, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la sensibilité individuelle."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison de l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition de la phospholipase A2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir l'inhibition."
}
},
{
"@type": "Question",
"name": "Les exercices physiques aident-ils à prévenir l'inhibition ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'inflammation et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut réduire le risque d'inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les compléments alimentaires sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments peuvent avoir des effets anti-inflammatoires, mais prudence."
}
},
{
"@type": "Question",
"name": "La gestion du stress peut-elle aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut réduire l'inflammation et améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour inhiber la phospholipase A2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation liée à l'inhibition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent avoir des effets inhibiteurs, mais peu prouvés."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs spécifiques sont-ils administrés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou injectable selon le médicament."
}
},
{
"@type": "Question",
"name": "Les traitements nécessitent-ils un suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies inflammatoires chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'allergies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir avec certains inhibiteurs de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'inhibition ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un ajustement du traitement sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'alimentation, le mode de vie et des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut augmenter le risque d'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il l'inhibition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber l'inflammation et l'inhibition."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies inflammatoires peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'inhibition peut augmenter avec l'âge en raison de l'inflammation."
}
}
]
}
]
}
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory factor in the pathogenesis of atherosclerotic plaque and is associated with an increased risk of ischemic stroke. Whether Lp-PLA2 i...
A total of 126 eligible AIS patients were divided into four groups: (1) no cerebral artery stenosis (NCS); (2) intracranial artery stenosis (ICAS); (3) extracranial artery stenosis (ECAS); and (4) com...
The ICAS group had a lower frequency of dyslipidemia as compared to the NCS group and the IECS group (35.3% vs. 70% vs. 71.8%, respectively,...
Elevated Lp-PLA2 levels were differentially associated with increased risk in AIS patients with ICAS compared to those with ECAS or no stenosis. Lp-PLA2 may be a promising biomarker and potential ther...
The food enzyme phospholipase A2 (phosphatidylcholine 2-acylhydrolase EC 3.1.1.4) is produced with the genetically modified...
The phospholipase A2 (PLA2) superfamily of phospholipase enzymes hydrolyzes the ester bond at the sn-2 position of the phospholipids, generating a free fatty acid and a lysophospholipid. The PLA2s are...
Nephrotic syndrome in pregnancy is associated with challenges for both patients and physicians. Early recognition is crucial, and when appropriate, renal biopsy should be considered to differentiate p...
A 6-month course of cyclophosphamide (CP) and steroids is effective in primary membranous nephropathy (MN), but unappealing because of long-term side effects. We evaluated efficacy of an "antibody-gui...
Patients with phospholipase A2 receptor (PLA2R)-related MN and high risk of progression were treated with CP 1.5 mg/kg/d and steroids in cycles of 8 weeks. Anti-PLA2R antibodies were measured by indir...
Our analysis included 65 patients (48 males, 17 females), age 61 ± 12 years, estimated glomerular filtration rate (eGFR) 46 ml/min per 1.73 m...
ABG is effective, and allows individualized therapy, with many patients responding to 8 weeks of CP-based therapy....
Acute gouty arthritis is inflammatory joint arthritis. Gouty arthritis (GA) involves multiple pathological processes. Deposition of joints by monosodium urate (MSU) crystals has been shown to play a c...
10 patients with gouty knee arthritis and 10 normal controls were selected from clinical, surgical cases. The biological function of the metabolome was assessed by co-expression network analysis. A mo...
Proteomic analysis showed that the expressions of proteases Cathepsin B, Cathepsin D, Cathepsin G, and Cathepsin S in synovial fluid patients with gouty arthritis were significantly increased. Enrichm...
Comprehensive analysis of proteomic and untargeted metabolomics revealed protein and characteristic metabolite alterations in gouty arthritis, it mainly involves lipids and lipid like molecules, phosp...
A wealth of evidence suggests that Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a relevant role in atherogenesis and inflammation, which in turn are associated with the risk of developing d...
Alzheimer's disease (AD) is a neurodegenerative disorder lacking any curative treatment up to now. Indeed, actual medication given to the patients alleviates only symptoms. The cytosolic phospholipase...
A cPLA...
We targeted the cPLA...
Showing a high affinity for the C2 domain of this enzyme, the peptide PLP25 exhibited an inhibitory effect on cPLA...
cPLA...
Overexpressed secretory phospholipase A2 (sPLA2) is found in many inflammatory diseases and various types of cancer. sPLA2 can catalyze the hydrolysis of phospholipid sn-2 ester bonds to lysophosphati...
S. Typhi, the cause of typhoid fever, is a bacterial pathogen of substantial global importance. Typhoid toxin is a secreted AB-type toxin that is a key S. Typhi virulence factor encoded within a 5-gen...